Non-clear cell RCC
PreferredClinical trial
Sunitinib
Other recommendedCabozantinib
Everolimus
Useful under certain circumstancesAxitinib
Bevacizumab
Erlotinib
Lenvatinib+everolimus
Nivolumab
Pazopanib
Bevacizumab+erlotinib for selected patients with advanced papillary RCC including HLRCC
Bevacizumab+everolimus
Temsirolimus

  • Adapted from NCCN Clinical Practice Guidelines in Oncology 70, version 2.2019; 9/17/18.

  • HLRCC, hereditary leiomyomatosis and RCC syndrome-associated RCC; RCC, renal cell cancer.